An Update on Checkpoint Inhibitors and CLL Where do we stand with immunotherapy for CLL patients? Experts Dr. Nicole Lamanna and Dr. Michael Keating provide an update on checkpoint inhibitors and their role in treating CLL. They explain how checkpoint inhibitors are making the cross over from solid tumors to hematological malignancies and, in particular, how they are used for targeted therapy for patients with Richter’s transformation. Get email alerts | Subscribe on YouTube | Like on Facebook | Follow on Twitter | Follow on Google+ |